Allied Minds portfolio company OcuTerra Therapeutics has secured $14.6m in funding.

OcuTerra Therapeutics, a US-based ophthalmology drug developer based on research at Harvard University, has completed a $14.6m series B round.
Investors in the round have not been identified.
Founded in 2011 as SciFluor Life Sciences, OcuTerra is working on a treatment, OTT166, for diabetic retinopathy, a condition affecting the back of the eye. It is a subsidiary of commercialisation firm Allied Minds.
The series B capital will support a phase 2 trial of OTT166.
OcuTerra previously raised $30m from unnamed investors in April 2015, after Allied Minds had supported a $5m series A round in August 2011.

Thierry Heles

Thierry Heles is the former editor-at-large of Global University Venturing and Global Corporate Venturing, and was the producer and host of the Beyond the Breakthrough podcast until December 2024.
Email LinkedIn